Implantica's Growing Presence in Italy with RefluxStop™ Innovation
Implantica AG, a pioneering medtech company committed to advancing medical technology, has recently expanded its services in Italy by opening the ninth RefluxStop™ Center of Excellence. This remarkable development highlights the company’s dedication to improving treatment options for patients suffering from gastroesophageal reflux disease (GERD), a condition affecting over a billion individuals globally.
Successful Procedures at Ospedale di Brunico
Dr. Günther Sitzmann, who leads the General Surgery Department at Ospedale di Brunico, successfully performed the first RefluxStop™ procedures recently. Under the support of renowned Prof. Dr. Moustafa Elshafei from Nordwest Hospital in Frankfurt, Germany, both patients exhibited positive recovery signs. Encouraged by this success, Dr. Sitzmann has already scheduled additional procedures for early in the upcoming month.
Significant Impact on GERD Treatment
Dr. Sitzmann expressed enthusiasm about this innovative approach by stating, "It's exciting to be at the start of a revolution in the surgical treatment of GERD with RefluxStop™ leading the way." The RefluxStop™ device is designed to provide chronic GERD patients with an effective surgical solution, enhancing their quality of life while minimizing the adverse effects often associated with traditional GERD treatments.
Increased Demand for Advanced Treatment
The addition of Ospedale di Brunico as a leading center to offer RefluxStop™ procedures comes amid a growing demand for advanced anti-reflux solutions in Italy. With estimates suggesting that around 11 million individuals in Italy struggle with GERD, this initiative is not only timely but essential. Economically, GERD poses a substantial burden on healthcare, costing the system significantly, while simultaneously detracting from patients' quality of life.
The Unique Mechanism of RefluxStop™
The RefluxStop™ procedure stands out from traditional treatments by addressing the root cause of GERD instead of merely alleviating symptoms. By restoring the body's natural anatomy and physiology, RefluxStop™ utilizes a unique mechanism of action that conserves the anti-reflux barrier's integrity without the need to encircle the food passageway, making it a safer option for a wider range of patients.
About Implantica AG
Implantica is a leading medtech company specializing in developing cutting-edge technologies focused on improving patient care. The RefluxStop™ device is a testament to their commitment and innovation, setting the stage for a groundbreaking shift in how GERD is treated. Implantica also explores eHealth solutions, featuring a patented product pipeline that promises to redefine medicine within the body.
For inquiries regarding RefluxStop™ or Implantica AG, you can reach out to Nicole Pehrsson, Chief Corporate Affairs Officer.
Frequently Asked Questions
What is RefluxStop™?
RefluxStop™ is an innovative medical device designed to treat GERD by restoring the anti-reflux barrier without compromising the natural anatomy of the esophagus.
How does the RefluxStop™ procedure work?
This procedure aims to reconstruct the body's natural physiology, effectively preventing acid reflux without involving the pressure-sensitive areas of the esophagus.
Where can I find RefluxStop™ treatment?
The treatment is currently available at various certified centers, including the newly established RefluxStop™ Center of Excellence at Ospedale di Brunico.
Who can benefit from RefluxStop™?
Patients suffering from chronic GERD looking for a safer surgical option typically benefit from the RefluxStop™ treatment.
What is Implantica's commitment?
Implantica is committed to providing advanced medical solutions that enhance patient care and transform the management of chronic conditions like GERD.
